REGorafenib vsTamoxifen in Patients With Platinum-sensitive OVARian Carcinoma and Isolated Biological Progression

Update l'année dernière
Reference: NCT02584465

Woman Man

  • | Country :
  • France
  • | organs :
  • -
  • | Specialty :
  • -

Extract

The objective of this randomized phase II is to evaluate the benefit of regorafenib for ovarian patients who reported a confirmed elevated CA-125 level under surveillance or bevacizumab, compared with tamoxifen.


Inclusion criteria

  • Ovarian Carcinoma

Links